NEW YORK, NY--(Marketwired - Apr 16, 2013) - With more and more acceptance of medical marijuana here in the U.S., companies like Nuvilex, Inc. (
The use of marijuana for medicinal purposes by those patients suffering from cancer is nothing new. However, the dramatic shift in opinion toward the drug in this country is new. As we've reported before, a recent Pew Research Center poll showed for the first time in 44 years of polling on the topic, that a majority of Americans were in favor of legalizing marijuana. This new shift could very well put pressure on those in Washington, D.C. and the remaining states that have not passed legislation legalizing marijuana or at the very least the compounds found in the drug that may prove vital to cancer research.
First in line at a shot at human clinical trials, could very well be a number of researchers at California Pacific Medical Center. Much like Nuvilex's subsidiary, they will initially utilize cannabidiol (CBD) as the basis for developing treatments for some of the deadliest forms of cancer. The group of doctors at California Pacific Medical Center has been working for more than five years studying cannabidiol which is one of the compounds found in Cannabis. CBD is non-toxic and unlike THC, it is not psychoactive which could very well gain it favor among the drug's detractors.
Two of the researchers involved in the study using CBD, Sean McAllister, Ph.D., and Pierre Desprez, Ph.D., both believe their work is ready for human trials, using the compound to treat metastatic cancer.
Continue reading this article at www.stockhousegroup.com/features
About Stock House Group
Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. We offer a platform to CEOs to develop their story through articles, Research Reports, and CEO Interviews. Additionally, we're building a library for Investors to research small and large cap stocks.